Table 4 Comparison between the early termination and continuous treatment groups
|  | Early termination group (n = 16) | Continuous treatment group (n = 14) | p value |
|---|---|---|---|
Baseline characteristics | |||
 Age | 73.0 [67.5, 76.5] | 71.5 [68.0, 74.0] | 0.601 |
 Gender (male/female) | 13/3 | 11/3 | 1.00 |
 Physique | |||
  Body weight (kg) | 52.6 [47.7, 57.8] | 58.5 [54.5, 66.3] | 0.048 |
  Body mass index | 19.1 [17.2, 21.1] | 21.9 [21.0, 24.2] | 0.007 |
  Body surface area (DuBois, m2) | 1.58 [1.47, 1.66] | 1.65 [1.51, 1.77] | 0.19 |
 Laboratory data | |||
  Creatinine (mg/dL) | 0.81 [0.68, 0.87] | 0.74 [0.68, 0.86] | 0.852 |
  Krebs von den Lungen-6 (U/mL) | 1021 [732, 1518] | 1047 [845, 2106] | 0.678 |
  Surfactant protein D (ng/dL) | 315 [186, 393] | 420 [273, 553] | 0.081 |
 Lung function test | |||
  % Forced vital capacity (%) | 48.5 [36.5, 58.6] | 56.6 [50.1, 69.7] | 0.212 |
  % DLco (%) | 45.1 [41.9, 58.6] | 42.4 [37.8, 53.3] | 0.499 |
Administration history of pirfenidone | |||
 Administration period (day) | 238 [146, 468] | 262 [127, 397] | 0.934 |
 Reason for discontinuation (%) | |||
  decline of forced vital capacity | 6 (37.5%) | 9 (64.3%) | 0.272 |
  adverse events | 10 (62.5%) | 5 (35.7%) |  |
 Maintenance dose (%) | |||
  < 1200 mg | 8 (50.0%) | 2 (14.3%) | 0.099 |
  1200 mg | 5 (31.2%) | 11 (78.6%) |  |
  1800 mg | 3 (18.8%) | 1 (7.1%) |  |